胰岛组织型纤溶酶原激活物/纤溶酶系统在人胰岛淀粉样多肽聚集时上调并保护β细胞免受聚集诱导的毒性
研究探讨组织型纤溶酶原激活物(tPA)/纤溶酶系统是否可减少人胰岛淀粉样多肽(hIAPP)聚集及其对β细胞的毒性。在hIAPP转基因小鼠胰岛、细胞模型及2型糖尿病供体胰岛中发现,淀粉样沉积过程中Plat表达和纤溶酶活性显著增加,纤溶酶可快速降解hIAPP并恢复细胞活力。结论提示增加胰岛纤溶酶活性可能是限制2型糖尿病β细胞丢失的策略。
要点
- hIAPP转基因小鼠胰岛在淀粉样沉积过程中Plat表达和纤溶酶活性显著增加(p≤0.01,n=5)。
- 纤溶酶剂量依赖性减少hIAPP纤维形成,并恢复INS-1β细胞活力(p≤0.01,n=5)。
- 2型糖尿病供体胰岛PLAT表达较无糖尿病供体显著增加2.4倍(p≤0.05)。
核心结论
- 纤溶系统在hIAPP聚集的胰岛中上调,纤溶酶快速降解hIAPP、限制其聚集为淀粉样物并保护β细胞免受hIAPP诱导的毒性。
- 增加胰岛纤溶酶活性可能是限制2型糖尿病β细胞丢失的策略。
研究设计与样本
- 研究检测了淀粉样倾向hIAPP转基因小鼠或非转基因对照小鼠离体胰岛在有无淀粉样抑制剂刚果红培养下的Plat表达和纤溶酶活性。
- 研究检测了hIAPP处理的原代胰岛内皮细胞、骨髓来源巨噬细胞(BMDM)和INS-1细胞的Plat表达。
- 研究采用无细胞硫黄素T试验和质谱分别监测hIAPP聚集动力学和纤溶酶对hIAPP的切割。
- 研究评估了有或无纤溶酶处理下hIAPP对INS-1β细胞活力的影响。
- 研究检测了有或无2型糖尿病供体新鲜分离胰岛的PLAT表达。
主要发现
- 转基因小鼠离体胰岛中,胰岛Plat表达和纤溶酶活性随淀粉样沉积过程显著增加(p≤0.01,n=5);非转基因小鼠胰岛未见这些效应,且刚果红可阻断这些效应(p≤0.01,n=4)。
- hIAPP暴露后,BMDM和INS-1细胞的Plat表达较溶剂处理细胞增加(p≤0.05,n=4),但胰岛内皮细胞无此变化。
- 无细胞系统中纤溶酶剂量依赖性减少hIAPP纤维形成,并恢复hIAPP诱导的INS-1β细胞活力丧失(p≤0.01,n=5)。
- 纤溶酶切割单体hIAPP,快速降低全长hIAPP丰度并出现hIAPP 1-11和12-37片段;含关键淀粉样生成区的hIAPP 12-37对INS-1细胞无毒性。
- 2型糖尿病供体胰岛PLAT表达较无2型糖尿病供体胰岛显著增加2.4倍(p≤0.05),2型糖尿病供体n=4,无糖尿病供体n=7。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Apart from its fibrinolytic activity, the tissue plasminogen activator (tPA)/plasmin system has been reported to cleave the peptide amyloid beta, attenuating brain amyloid deposition in Alzheimer's disease. As aggregation of human islet amyloid polypeptide (hIAPP) is toxic to beta cells, we sought to determine whether activation of the fibrinolytic system can also reduce islet amyloid deposition and its cytotoxic effects, which are both observed in type 2 diabetes. METHODS: The expression of Plat (encoding tPA) and plasmin activity were measured in isolated islets from amyloid-prone hIAPP transgenic mice or non-transgenic control islets expressing non-amyloidogenic mouse islet amyloid polypeptide cultured in the absence or presence of the amyloid inhibitor Congo Red. Plat expression was also determined in hIAPP-treated primary islet endothelial cells, bone marrow-derived macrophages (BMDM) and INS-1 cells, in order to determine the islet cell type(s) producing tPA in response to hIAPP aggregation. Cell-free thioflavin-T assays and MS were used to respectively monitor hIAPP aggregation kinetics and investigate plasmin cleavage of hIAPP. Cell viability was assessed in INS-1 beta cells treated with hIAPP with or without plasmin. Finally, to confirm the findings in human samples, PLAT expression was measured in freshly isolated islets from donors with and without type 2 diabetes. RESULTS: In isolated islets from transgenic mice, islet Plat expression and plasmin activity increased significantly with the process of amyloid deposition (p≤0.01, n=5); these effects were not observed in islets from non-transgenic mice and were blocked by Congo Red (p≤0.01, n=4). In response to hIAPP exposure, Plat expression increased in BMDM and INS-1 cells vs vehicle-treated cells (p≤0.05, n=4), but not in islet endothelial cells. Plasmin reduced hIAPP fibril formation in a dose-dependent manner in a cell-free system, and restored hIAPP-induced loss of cell viability in INS-1 beta cells (p≤0.01, n=5). Plasmin cleaved monomeric hIAPP, inducing a rapid decrease in the abundance of full-length hIAPP and the appearance of hIAPP 1-11 and 12-37 fragments. hIAPP 12-37, which contains the critical amyloidogenic region, was not toxic to INS-1 cells. Finally, PLAT expression was significantly increased by 2.4-fold in islets from donors with type 2 diabetes (n=4) vs islets from donors without type 2 diabetes (n=7) (p≤0.05). CONCLUSIONS/INTERPRETATION: The fibrinolytic system is upregulated in islets with hIAPP aggregation. Plasmin rapidly degrades hIAPP, limiting its aggregation into amyloid and thus protecting beta cells from hIAPP-induced toxicity. Thus, increasing islet plasmin activity might be a strategy to limit beta cell loss in type 2 diabetes.
引用
- Esser N, Hogan MF, Templin AT, et al. The islet tissue plasminogen activator/plasmin system is upregulated with human islet amyloid polypeptide aggregation and protects beta cells from aggregation-induced toxicity. Diabetologia. 2024. PMID: 39245780. doi:10.1007/s00125-024-06161-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。